公开(公告)号：US20220204518A1

公开(公告)日：2022-06-30

申请号：US17606121

申请日：2020-04-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao ZHANG ,  Jian DING ,  Hua XIE ,  Zilan SONG ,  Yu XUE ,  Li XING ,  Linjiang TONG ,  Meiyu GENG

IPC: C07D487/14 ,  A61P35/00

Abstract: The present invention relates to a pyrimido[5,4-b]pyrrolizin compound represented by general formula I, an optical isomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use thereof. The compound according to the present invention has good inhibitory activity on the kinase BTK at both the molecular level and the cellular level. Meanwhile, the compound also has good anti-tumor activity and pharmacokinetic properties in vivo.

公开(公告)号：US20200172510A1

公开(公告)日：2020-06-04

申请号：US15998927

申请日：2017-02-17

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Ao ZHANG ,  Meiyu GENG ,  Li XING ,  Jing AI ,  Zilan SONG ,  Xia PENG ,  Wangting GU ,  Jian DING

IPC: C07D401/12 ,  C07D403/12 ,  C07D413/14 ,  C07D417/14 ,  C07D405/12 ,  C07D213/75 ,  A61P35/00

Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.